Related Experiment Video
Updated: Aug 20, 2026

In Vivo Thoracic Dorsal Root Ganglia (DRG) Calcium Imaging and ECG Recording for Studying Peripheral Nerve Stimulation
Published on: August 16, 2024
Voltage-gated calcium channels as targets for the treatment of chronic pain
Joseph G McGivern1, Stefan I McDonough
1Department of HTS-Molecular Pharmacology, Amgen Inc., Thousand Oaks, California 91320, USA. mcgivern@amgen.com
Abstract:
This review focuses on the importance of voltage-gated calcium channels in modulating and controlling the function of peripheral and central neurons involved in nociceptive processing. We describe the different families of voltage-gated calcium channels that are expressed in pain pathway neurons, how the expression levels of calcium channel currents change in chronic pain conditions, and the validation of N-type, T-type, and P-type calcium channels as targets for the treatment of pain. The molecular mechanism of action is reviewed for the most prominent calcium channel-targeted drugs including gabapentin and ziconotide as well as antiepileptics administered off-label for the treatment of pain. We discuss how the major genetic, functional, and pharmacological differences between subtypes of neuronal calcium channels can be leveraged to identify new molecular targets and to discover and develop new therapeutic agents for the treatment of chronic pain syndromes.
Insights
Voltage-gated calcium channels are crucial for pain signaling. Targeting specific channel types offers a promising strategy for developing novel chronic pain treatments.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Voltage-gated calcium channels (VGCCs) play a critical role in neuronal excitability and neurotransmitter release.
- Dysregulation of VGCCs is implicated in the pathophysiology of chronic pain states.
Purpose of the Study:
- To review the role of VGCCs in nociception.
- To evaluate VGCCs as therapeutic targets for pain management.
- To discuss the development of novel pain therapeutics targeting VGCCs.
Main Methods:
- Literature review of studies on VGCCs in pain pathways.
- Analysis of expression changes in chronic pain.
- Examination of drug mechanisms targeting VGCCs.
Main Results:
- Specific VGCC subtypes (N-type, T-type, P-type) are key players in pain processing.
- Altered VGCC expression and function are observed in chronic pain conditions.
- Drugs like gabapentin and ziconotide demonstrate the therapeutic potential of targeting VGCCs.
Conclusions:
- Neuronal VGCCs are validated targets for treating pain.
- Understanding subtype-specific differences can guide the development of more effective pain medications.
- Leveraging genetic and pharmacological variations may lead to new chronic pain therapies.
Related Concept Videos
Voltage-gated Ion Channels
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several types of...
Voltage-gated Ion Channels
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several types of...
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Non-gated Ion Channels
Compared to the gated ion channels, the non-gated channels, also known as leakage or passive channels, have no gating mechanism.
Mechanically-gated Ion Channels
Analgesia and Pain Management
